

Creo Medical Group "really pleased" with first human trial of lung lesion treatment



DIGITAL ASSET DIRECT BY CREO MEDICAL GROUP PLC

London, UK | May 26, 2023 11:07 AM Eastern Daylight Time



Creo Medical Group PLC (AIM:CREO) CEO Craig Gulliford speaks to Thomas Warner from Proactive after announcing the successful completion of a first human trial of its pioneering MicroBlate Flex device for soft tissue lung lesion microwave ablation. Gulliford reveals the difference he believes the product could ultimately make to people suffering from early-stage lung cancer, saying that he's "really pleased that we've had a great outcome so far."

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

Tags

CREO MEDICAL

MEDICAL DEVICES

HEALTHCARE

PROACTIVE

INVESTOR

STOCKS